In­vivyd scores EUA for Covid-19 pre­ven­tion drug Pem­gar­da

The FDA gave the green light to In­vivyd’s Pem­gar­da for Covid-19 pre­ven­tion in high-risk im­muno­com­pro­mised pa­tients, is­su­ing an emer­gency use au­tho­riza­tion on Fri­day for the mon­o­clon­al an­ti­body.

The drug is ap­proved for pa­tients 12 years and old­er who are un­like­ly to de­vel­op an ad­e­quate im­mune re­sponse from vac­ci­na­tion, aren’t cur­rent­ly in­fect­ed with the virus or have been re­cent­ly ex­posed to Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER